Table 3 Anti-MCV IgA titer courses of responders and non-responders to RTX in relation to their achieved DAS28 response after six months of RTX treatment (according to the EULAR response criteria)
Responders to RTX (RRs) | |||
DAS28 response of 37 RRs at week 24 (number of RRs) | mean AMCV IgA titer at baseline (U/ml) | mean AMCV IgA titer at week 24 (U/ml) | percentage change (absolute titer change) |
DAS28 ≤2.6 remission (12/37) | 141.94 | 30.00 | 78.86 % (111.93) |
DAS28 ≤3.2 and >2.6 low disease activity (5/37) | 33.85 | 17.06 | 49.61 % (16.79) |
DAS28 ≤5.1 and >3.2 moderate disease activity (17/37) | 83.52 | 37.26 | 55.39 % (46.26) |
DAS28 >5.1 high disease activity (3/37) | 14.32 | 8.45 | 41.00 % (8.87) |
Non-responders to RTX (NRRs) | |||
DAS28 response of 13 NRRs at week 24 (number of NRRs) | mean AMCV IgA titer at baseline (U/ml) | mean AMCV IgA titer at week 24 (U/ml) | percentage change (absolute titer change) |
DAS28 ≤2.6 remission (0/13) | / | / | / |
DAS28 ≤3.2 and>2.6 low disease activity (1/13) | 46.11 | 55.56 | 17.01 % (9.45) |
DAS28 ≤5.1 and >3.2 moderate disease activity (7/13) | 290.79 | 270.51 | 06.97 % (20.27) |
DAS28 >5.1 high disease activity (5/13) | 71.41 | 221.49 | 67.76 % (150.08) |